An open labled study to evaluate the efficacy and safety of valiliv® capsules in the patients with viral hepatitis

Liver is a vital organ play a major role in metabolism and excretion of xenobiotics from the body. Liver cell injury is generally caused by various toxic chemicals (certain anti-biotic, chemotherapeutic agents, carbon tetrachloride (CCl4), thioacetamide (TAA) etc.), excessive alcohol consumption and microbes is well-studied. The available synthetic drugs to treat liver disorders in this condition also cause further damage to the liver. Hence, Herbal drugs have become increasingly popular and their use is wide-spread. Herbal medicines have been used in the treatment of liver diseases for a long time so the maintenance of a healthy liver is get possible. Current open labeled study of Valiliv capsule a preparation of extract of Kutki (Picrorrhiza kurroa) and bhui-awala (Phyllanthus niruri) in capsule form was studied in a cases of acute viral hepatitis cases caused due to HAV for the period of 12 week in a dose of 2 capsules BID. Highly significant results even after 4 week of treatment in biochemical parameters of billirubin, ALT, AST, WBC indicates the significance hepatoprotective effect of the therapy with highly significant difference in clinical parameters like anorexia, pain in abdomen etc. without causing any untoward effect during the therapy.